The introduction of a 750mcg parathyroid hormone injection in Australia has been relatively limited , with distribution primarily through specialist physicians and designated treatment centers. Preliminary sales figures for this higher dosage remain unavailable from the company, although reports suggest controlled adoption rates . Patient access is